<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669669</url>
  </required_header>
  <id_info>
    <org_study_id>2000.00</org_study_id>
    <secondary_id>NCI-2013-00701</secondary_id>
    <secondary_id>8357</secondary_id>
    <secondary_id>2000.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00669669</nct_id>
  </id_info>
  <brief_title>O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas</brief_title>
  <official_title>Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of temozolomide when given
      together with radiation therapy, carmustine, O6-benzylguanine, and patients' own stem cell
      (autologous) transplant in treating patients with newly diagnosed glioblastoma multiforme or
      gliosarcoma. Giving chemotherapy, such as temozolomide, carmustine, and O6-benzylguanine, and
      radiation therapy before a peripheral stem cell transplant stops the growth of cancer cells
      by stopping them from dividing or killing them. Giving colony-stimulating factors, such as
      filgrastim or plerixafor, and certain chemotherapy drugs, helps stem cells move from the bone
      marrow to the blood so they can be collected and stored. Chemotherapy or radiation therapy is
      then given to prepare the bone marrow for the stem cell transplant. The stem cells are then
      returned to the patient to replace the blood-forming cells that were destroyed by the
      chemotherapy and radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the safety and feasibility of infusing autologous granulocyte colony-stimulating
      factor (G-CSF) (filgrastim) mobilized stem cells transduced with a Phoenix-gibbon ape
      leukemia virus (GALV)-pseudotype vector expressing methylguanine methyltransferase (MGMT)
      (P140K).

      II. Define the dose of BCNU (carmustine) that results in efficient engraftment of gene
      modified cells when given with peripheral blood stem cell support.

      SECONDARY OBJECTIVES:

      I. Determine the engraftment of gene-modified cells after conditioning with BCNU.

      II. Determine the ability to select gene-modified cells in vivo with this regimen.

      III. Evaluate the molecular and clonal composition of gene-modified cells after chemotherapy
      with temozolomide.

      IV. Observe patients for clinical anti-tumor response.

      V. Determine the correlation of the level of MGMT (P140K) marking with toxicity, temozolomide
      dose achieved, and response.

      VI. Characterize the toxicity associated with this regimen.

      OUTLINE: This is a phase I, dose-escalation study of temozolomide followed by a phase II
      study.

      PART I: Within 35 days of surgery, patients undergo 3 dimensional (3D) conformal
      intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy daily 5 days
      per week for 6 weeks. Patients receive filgrastim subcutaneously (SC) on days -7 to -3 and
      begin stem cell collection on the 4th day of filgrastim administration (up to 3 apheresis).
      Patients may also receive plerixafor SC on days -5 to -3. The CD34+ stem cells are separated
      from the patient's stem cells and they are transduced with Phoenix-RD114 pseudotype vector
      (retrovirus). One day after apheresis is completed, patients receive carmustine intravenously
      (IV) over 3 hours followed 2 hours later by temozolomide orally (PO). At least twenty-four
      hours after completion of carmustine and temozolomide, patients undergo reinfusion of
      genetically-modified stem cells.

      PART II: Beginning approximately 4 weeks after completion of Phase 1 of the study, patients
      receive O6-benzylguanine IV continuously over 48 hours followed by temozolomide PO within 1
      hour. Treatment may repeat at least every 28 days for a total of 24 courses in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed every 1-3 months for 2 years,
      every 3-6 months for 3 years, and then annually thereafter for 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 25, 2009</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity (DLT) defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I)</measure>
    <time_frame>Up to 6 weeks after infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of DLT (Part II)</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of replication competent retrovirus or leukemia</measure>
    <time_frame>Up to 2 years after infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>From the first day of treatment until death, assessed up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From the first day of treatment until unequivocal progression is documented, assessed up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene transfer efficiency and in vivo selection, assessed by gene marking in peripheral blood and marrow</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemoprotection, assessed by the ability to increase the temozolomide dose beyond 472 mg/m^2</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-Dimensional Conformal Radiation Therapy</intervention_name>
    <description>Undergo 3D conformal IMRT</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>3-dimensional radiation therapy</other_name>
    <other_name>3D CONFORMAL RADIATION THERAPY</other_name>
    <other_name>3D CRT</other_name>
    <other_name>3D-CRT</other_name>
    <other_name>Conformal Therapy</other_name>
    <other_name>Radiation Conformal Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous in vitro-treated peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>Gliadel</other_name>
    <other_name>N,N'-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>Filgrastim XM02</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tbo-filgrastim</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>In Vitro-Treated Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous in vitro-treated peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>in vitro-treated PBPC transplantation</other_name>
    <other_name>in vitro-treated peripheral blood progenitor cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo 3D conformal IMRT</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O6-Benzylguanine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>6-O-BENZYLGUANINE</other_name>
    <other_name>O(6)-Benzylguanine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>AMD 3100</other_name>
    <other_name>JM-3100</other_name>
    <other_name>Mozobil</other_name>
    <other_name>SDZ SID 791</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Beam Radiation Therapy</intervention_name>
    <description>Undergo proton beam radiation therapy</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>CCRG-81045</other_name>
    <other_name>Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-</other_name>
    <other_name>M &amp; B 39831</other_name>
    <other_name>M and B 39831</other_name>
    <other_name>Methazolastone</other_name>
    <other_name>RP-46161</other_name>
    <other_name>SCH 52365</other_name>
    <other_name>Temcad</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>Temomedac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with glioblastoma multiforme or gliosarcoma

          -  The patient or legal guardian must be able to comprehend the informed consent form and
             sign prior to patient enrollment

          -  Karnofsky performance status at time of study entry must be &gt;= 70%

          -  Life expectancy of &gt;= 3 months

          -  Patients must agree to undergo repeat clinical neurological examinations and brain
             magnetic resonance imaging (MRI) with appropriate contrast after every other cycle of
             chemotherapy

          -  White blood cell (WBC) &gt; 3000/ul

          -  Absolute neutrophil count (ANC) &gt; 1500/ul

          -  Platelets &gt; 100,000/ul

          -  Hemoglobin &gt; 10 gm/100ml

          -  Total and direct bilirubin &lt; 1.5 times upper limit of laboratory normal

          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate
             transaminase (SGPT) =&lt; 3 times upper limit of laboratory normal

          -  Alkaline phosphatase =&lt; 3 times upper limit of laboratory normal

          -  Blood urea nitrogen (BUN) &lt; 1.5 times upper limit of laboratory normal

          -  Serum creatinine &lt; 1.5 times upper limit of laboratory normal

          -  Left ventricular ejection fraction (LVEF) &gt;= 40%, however, subjects with a LVEF in the
             range of 40-49% should have cardiology clearance prior to intervention

          -  MGMT promoter methylation analysis of surgically resected tumor or tumor biopsy must
             demonstrate an unmethylated or hypomethylated MGMT promoter status

        Exclusion Criteria:

          -  Patients with cardiac insufficiency and a LVEF of &lt; 40%; history of coronary artery
             disease or arrhythmia, which has required or requires ongoing treatment

          -  Patients with active pulmonary infection and/or pulse oximetry &lt; 90% and a corrected
             diffusion capacity of the lung for carbon monoxide (DLCO) &lt; 70% of predicted

          -  Active systemic infection

          -  Patients who are human immunodeficiency virus (HIV) positive

          -  Pregnant or lactating women; a beta-human chorionic gonadotropin (HCG) level will be
             obtained from women of childbearing potential; fertile men and women should use
             effective contraception

          -  Previous chemotherapy for any malignancy including temozolomide, dacarbazine (DTIC) or
             prior nitrosourea

          -  Diabetes mellitus

          -  Bleeding disorder

          -  Methylated or hypermethylated MGMT promoter status within tumor tissue

          -  Medical or psychiatric condition which in the opinion of the protocol chairman would
             compromise the patient's ability to tolerate this protocol

          -  Prior interstitial radiotherapy, stereotactic or gamma knife surgery or implanted
             BCNU-wafers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Peter Kiem</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>O(6)-benzylguanine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

